Moreover, inclusion of patients with benign disease would further support the malignant nature of the elevated IL4I1 metabolism, while a direct comparison between metabolite levels in ascites and tumor biopsies from the same patients could substantiate the use of ascites over biopsies for biomarker evaluation. Here, IL4I1 is linked to neoplasm.